Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109917 | 0.80 | HRH3 (1.00) | HRH3TSHRALDH1A1KCNH2LMNA | |
| SCHEMBL5106629 | 0.80 | HRH3 (0.68) | HRH3KCNA5 | |
| SCHEMBL5100586 | 0.80 | HRH3 (0.70) | HRH3KCNA5KCNH2 | |
| SCHEMBL6152212 | 0.78 | TSHR (0.45) | HRH3TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL6110825 | 0.78 | HRH3 (0.61) | HRH3ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL5093846 | 0.70 | HRH3 (1.00) | HRH3 | |
| SCHEMBL14287747 | 0.70 | HRH3 (1.00) | HRH3 | |
| Hydrochloric Acid SCHEMBL5935388 | 0.69 | HRH1 (0.68) | HRH3KCNA5KCNH2 | |
| SCHEMBL9121163 | 0.67 | KMT2A (0.81) | HRH3TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL10568708 | 0.67 | POLB (0.52) | ALDH1A1KDM4EKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167046-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167046-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | HRH3 1/4885TSHR 346/4885KCNA5 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.